Wall Street Thinks Madrigal Pharmaceuticals Could Climb 93%. Here's Why It Could Happen Soon.The Motley Fool • 09/27/23
Madrigal Pharmaceuticals Surges As Its NASH Treatment Toes The Long-Awaited Finish LineInvestors Business Daily • 09/13/23
Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver FibrosisGlobeNewsWire • 09/13/23
3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy?The Motley Fool • 08/23/23
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/08/23
Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver FibrosisGlobeNewsWire • 07/15/23
Madrigal Pharmaceuticals' stock up 5% as company starts rolling submission for FDA approval of NASH treatmentMarket Watch • 06/30/23
Madrigal Stock Pops As It Makes Inroads Into What Could Be A $160 Billion MarketInvestors Business Daily • 06/30/23
Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver FibrosisGlobeNewsWire • 06/30/23
Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™GlobeNewsWire • 06/22/23